Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753293 | 0.86 | RXRA (0.41) | DPP4DPP7RXRARXRBRXRG | |
| SCHEMBL732702 | 0.86 | RXRA (0.41) | DPP4DPP7RXRARXRBRXRG | |
| SCHEMBL474564 | 0.85 | AR (0.36) | ARHSD11B1RXRARXRBRXRG | |
| SCHEMBL480779 | 0.84 | AR (0.41) | ARHSD11B1 | |
| SCHEMBL479974 | 0.83 | AR (0.35) | ARHSD11B1RXRARXRBRXRG | |
| SCHEMBL734223 | 0.81 | PDK2 (0.36) | ARDPP4DPP7RXRARXRB | |
| SCHEMBL755587 | 0.81 | PDK2 (0.36) | ARDPP4DPP7RXRARXRB | |
| SCHEMBL732428 | 0.81 | DPP4 (0.34) | DPP4DPP7RXRARXRBPDE2A | |
| SCHEMBL755583 | 0.81 | DPP4 (0.34) | DPP4DPP7RXRARXRBPDE2A | |
| SCHEMBL753053 | 0.80 | GRIK1 (0.35) | DPP4DPP7PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411361-B1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-8138189-B2 | Substituted benzene compounds as modulators of the glucocorticoid receptor | HOFFMAN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, CRHR1 | AR 187/4885HSD11B1 11/4885DPP4 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.